As­traZeneca’s triplet with Imfinzi, treme and chemo works on a key end­point for front­line lung can­cer

As­traZeneca’s big come­back year just got bet­ter.
Af­ter dis­ap­point­ing in­vestors with re­peat­ed set­backs on their PD-L1/CT­LA-4 matchup of Imfinzi and treme­li­mum­ab, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER